Seres Therapeutics Inc
MCRB14.140USD
+0.150+1.07%
交易中 （美東）報價延遲15分鐘
6.17M總市值
0.08本益比TTM
關於 Seres Therapeutics Inc 公司
Seres Therapeutics, Inc. 是一家臨牀階段公司，專注於通過新型活體生物療法改善醫學上脆弱人羣的患者治療效果。該公司致力於開發 SER-155，在接受異基因造血幹細胞移植 (allo-HSCT) 的患者的臨牀研究中，該藥物已證明顯著減少血液感染和相關併發症（與安慰劑相比）。該公司還在推進針對醫學上脆弱人羣的其他培養口服活體生物療法，包括患有慢性肝病、癌症中性粒細胞減少症和實體器官移植的患者。該公司在其各個項目中的臨牀和非臨牀數據支持開發活體生物療法，以預防和治療廣泛的感染以及炎症和免疫疾病。
公司簡介
公司代碼MCRB
公司名稱Seres Therapeutics Inc
上市日期Jun 26, 2015
CEOMr. Thomas J. DesRosier, J.D.
員工數量103
證券類型Ordinary Share
年結日Jun 26
公司地址101 Cambridge Park Drive
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02140
電話16179459626
網址https://www.serestherapeutics.com/
公司代碼MCRB
上市日期Jun 26, 2015
CEOMr. Thomas J. DesRosier, J.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Thomas J. DesRosier, J.D.
Mr. Thomas J. DesRosier, J.D.
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
7.29K
+2.32%
Dr. Matthew R. Henn, Ph.D.
Dr. Matthew R. Henn, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
4.38K
+3.81%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
3.17K
--
Dr. Teresa L. Young, Ph.D.
Dr. Teresa L. Young, Ph.D.
Executive Vice President, Chief Commercial and Strategy Officer
Executive Vice President, Chief Commercial and Strategy Officer
--
--
Mr. Paul R. Biondi
Mr. Paul R. Biondi
Independent Director
Independent Director
--
--
Mr. Stephen A. Berenson
Mr. Stephen A. Berenson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
--
--
Dr. Claire M. Fraser, Ph.D.
Dr. Claire M. Fraser, Ph.D.
Independent Director
Independent Director
--
--
Dr. Hans-Juergen Woerle, M.D., Ph.D.
Dr. Hans-Juergen Woerle, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Marella Thorell
Ms. Marella Thorell
Co-President, Co-Chief Executive Officer, Chief Financial Officer
Co-President, Co-Chief Executive Officer, Chief Financial Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Thomas J. DesRosier, J.D.
Mr. Thomas J. DesRosier, J.D.
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
7.29K
+2.32%
Dr. Matthew R. Henn, Ph.D.
Dr. Matthew R. Henn, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
4.38K
+3.81%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
3.17K
--
Dr. Teresa L. Young, Ph.D.
Dr. Teresa L. Young, Ph.D.
Executive Vice President, Chief Commercial and Strategy Officer
Executive Vice President, Chief Commercial and Strategy Officer
--
--
Mr. Paul R. Biondi
Mr. Paul R. Biondi
Independent Director
Independent Director
--
--
Mr. Stephen A. Berenson
Mr. Stephen A. Berenson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
收入明細
FY2023
FY2022
FY2021
暫無數據
地區USD
名稱
營收
佔比
United States
126.33M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Flagship Ventures
13.24%
Fidelity Management & Research Company LLC
12.51%
Nestle SA
12.47%
The Vanguard Group, Inc.
3.49%
BlackRock Institutional Trust Company, N.A.
0.96%
Other
57.33%
持股股東
持股股東
佔比
Flagship Ventures
13.24%
Fidelity Management & Research Company LLC
12.51%
Nestle SA
12.47%
The Vanguard Group, Inc.
3.49%
BlackRock Institutional Trust Company, N.A.
0.96%
Other
57.33%
股東類型
持股股東
佔比
Investment Advisor
19.23%
Venture Capital
13.24%
Corporation
12.47%
Investment Advisor/Hedge Fund
1.46%
Research Firm
1.04%
Individual Investor
0.59%
Hedge Fund
0.45%
Bank and Trust
0.05%
Other
51.47%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
284
4.24M
48.53%
-1.00M
2025Q1
303
4.22M
48.29%
-1.11M
2024Q4
311
85.93M
50.33%
-20.68M
2024Q3
330
86.09M
50.57%
-26.54M
2024Q2
336
69.70M
45.95%
-51.91M
2024Q1
345
94.53M
65.81%
-35.72M
2023Q4
345
98.23M
75.49%
-30.72M
2023Q3
356
117.05M
93.47%
-19.47M
2023Q2
384
121.97M
97.71%
-18.66M
2023Q1
378
115.00M
93.33%
-29.90M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Flagship Ventures
1.16M
13.24%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
1.09M
12.51%
+2.16K
+0.20%
Mar 31, 2025
Nestle SA
1.09M
12.47%
+709.39K
+186.83%
Sep 30, 2024
The Vanguard Group, Inc.
304.60K
3.49%
+10.91K
+3.71%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
84.10K
0.96%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
80.94K
0.93%
+5.42K
+7.17%
Mar 31, 2025
Bank Vontobel AG
54.30K
0.62%
+7.38K
+15.74%
Mar 31, 2025
UBS Financial Services, Inc.
69.22K
0.79%
+52.11K
+304.43%
Mar 31, 2025
Charles Schwab Investment Management, Inc.
41.70K
0.48%
-1.59K
-3.66%
Mar 31, 2025
Susquehanna International Group, LLP
35.86K
0.41%
+19.47K
+118.77%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0%
Direxion Daily S&P Biotech Bull 3X Shares
0%
iShares Russell 2000 Growth ETF
0%
iShares Biotechnology ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
FlexShares Morningstar US Market Factor Tilt Index Fund
0%
Proshares Ultra Russell 2000
0%
查看更多
iShares Micro-Cap ETF
佔比0.01%
Invesco RAFI US 1500 Small-Mid ETF
佔比0%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
iShares Biotechnology ETF
佔比0%
Invesco Nasdaq Biotechnology ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
FlexShares Morningstar US Market Factor Tilt Index Fund
佔比0%
Proshares Ultra Russell 2000
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
